tbuckley/cabot-search huggingface dataset:
Nucleic Acids and Protein Nitrogen in Regenerated Liver of the Cirrhotic Rat
Authors: N RABINOVICI, E WIENER
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression
Authors: S Avissar, Y Nechamkin, G Roitman, G Schreiber
Journal: American Journal of Psychiatry (1997)

Heterotrimeric G proteins play a pivotal role in postreceptor information transduction. These proteins were previously implicated in the biochemical mechanism underlying lithium action and in the pathophysiology of mood disorders. The present study sought to quantitatively and functionally evaluate G proteins in patients with major depression.G proteins were measured in mononuclear leukocytes of 37 untreated patients with major depression and 31 comparison subjects. Receptor-coupled G protein function was evaluated through beta-adrenergic and muscarinic-agonist-induced increases in guanine nucleotide binding capacity, which were substantiated by quantitative measures of G proteins through immunoblot analyses that used polyclonal antibodies against stimulatory (Gs alpha) and inhibitory (Gi alpha) G proteins.Mononuclear leukocytes of depressed patients showed significantly reduced immunoreactive quantities of Gs alpha and Gi alpha together with markedly hypofunctional Gs and Gi. The reductions in both function and quantity of Gs and Gi were significantly correlated with the severity of depressive symptoms. Moreover, simultaneous quantitative and functional measurements in a large number of patients showed significant correlations between the function and the quantity of mononuclear leukocyte Gs and Gi proteins:These findings lend further support to the implication of G proteins in the pathophysiology of mood disorders. G protein functional and quantitative measurements in mononuclear leukocytes of patients with mood disorders may potentially serve as a biochemical marker for the affective state of these patients.
PWE-379 The measurement and assessment of rectocoele using ultrasound and proctography
Authors: AJ Hainsworth, E Collins, D Solanki, N Griffin, AM Schizas, AB Williams
Journal: Gut (2015)

<h3>Introduction</h3> Defaecation proctography is the current gold standard for the evaluation of defaecatory dysfunction, which includes the assessment of rectocoele, but entails radiation exposure. Defaecation MRI is an alternative but is expensive and not easily available. Pelvic floor ultrasound is an emerging imaging modality for the assessment of pelvic floor pathology, including defaecatory dysfunction. This study aims to; - assess inter- and intra-rater repeatability of rectocoele assessment by both transperineal ultrasound (USS) and proctography - compare rectocoele assessment between the two imaging modalities. <h3>Method</h3> The images of 66 patients who had had undergone both USS and defaecatory proctography were retrospectively reviewed by four interpreters blinded to clinical symptoms and other imaging results. Transperineal ultrasound was performed on coughing, squeezing and bearing down. Defaecation proctography was performed with rectal and oral contrast. Rectocoele measurement on ultrasound was determined by the protrusion of the rectal wall beyond the perineal body into the vagina. Rectocoele measurement on proctography was the distance beyond a single line from the projected anterior rectal wall to the furthermost point of the rectocoele. Bland Altman analysis was performed to determine agreement. <h3>Results</h3> There was excellent inter and intra – rater agreement for rectocoele measurement on proctography (intra-class correlation coefficient 0.91 for both). There was excellent inter – rater agreement (intra-class correlation coefficient 0.78) and good intra - rater agreement (intra-class correlation coefficient 0.67) for rectocoele measurement on USS. There was moderate agreement between rectocoele measurement on ultrasound and that on proctography (intra-class correlation coefficient 0.46). There was a strong positive correlation between measurements on ultrasound compared to proctography (correlation coefficient 0.59). Rectocoele measurement was 1.25 cm larger on proctography than on ultrasound. <h3>Conclusion</h3> The measurement of rectocoeles on both proctography and ultrasound shows good to excellent inter – and intra – rater repeatability. There is a good correlation between measurements on ultrasound compared with proctography. Not surprisingly, measurements are larger using proctography where protrusion of the rectal wall is measured. By contrast ultrasound measures the protrusion over the perineal body into the vagina. Clearly, proctography may over-diagnose rectocoele. The next main consideration is how size on each modality correlates with function and clinical symptoms. <h3>Disclosure of interest</h3> None Declared.
In Vivo Antitumor Activity of Tumor-Infiltrating Lymphocytes Expanded in Recombinant Interleukin-2
Authors: P J Spiess, J C Yang, S A Rosenberg
Journal: JNCI Journal of the National Cancer Institute (1987)

Journal Article In Vivo Antitumor Activity of Tumor-Infiltrating Lymphocytes Expanded in Recombinant Interleukin-2 Get access Paul J. Spiess, Paul J. Spiess Search for other works by this author on: Oxford Academic PubMed Google Scholar James C. Yang, James C. Yang Search for other works by this author on: Oxford Academic PubMed Google Scholar Steven A. Rosenberg Steven A. Rosenberg Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 79, Issue 5, November 1987, Pages 1067–1075, https://doi.org/10.1093/jnci/79.5.1067 Published: 01 November 1987 Article history Received: 06 January 1987 Accepted: 02 July 1987 Published: 01 November 1987
Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)
Authors: Jacob P. Laubach, Jesús F San Miguel, Pieter Sonneveld, Robert Z. Orlowski, Philippe Moreau, Laura Rosiñol, Javid J Moslehi, Edward A Faber, Peter M Voorhees, Loreta Marquez, Avinash Desai, Helgi van de Velde, Jennifer Elliott, Hongliang Shi, Edward Dow, Nishith Jobanputra, Dixie-Lee Esseltine, Liviu Niculescu, Kenneth C. Anderson, Sagar Lonial, Paul G. Richardson
Journal: Blood (2013)
“Impressive results” in stem cell treatment for multiple sclerosis
Authors: Susan Mayor
Journal: BMJ (2016)

Aggressive immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT) halted clinical relapses and the development of new brain lesions for a prolonged period in most patients with multiple sclerosis (MS) taking part in a small early stage trial, results published in the Lancet have shown.1

Some 23 of the 24 patients taking part in the phase II trial showed no further clinical relapses or development of new brain lesions. And eight of those 23 showed sustained improvement in disability an average of 7.5 years after the stem cell transplant, which is the first therapeutic approach to achieve this level of disease control or neurological …
Usefulness of triphasic CT aortic angiography in acute and surveillance: Our experience in the assessment of acute aortic dissection and endoleak
Authors: Alfonso Reginelli, Raffaella Capasso, Vincenzo Ciccone, Maria Rosaria Croce, Graziella Di Grezia, Mattia Carbone, Nicola Maggialetti, Antonio Barile, Paolo Fonio, Michele Scialpi, Luca Brunese
Journal: International Journal of Surgery (2016)
Mutagenicity of Nitrosourea Compounds for Salmonella typhimurium: Brief Communication 2
Authors: Angela E. Auletta, Anne G. Martz, Amar S. Parmar
Journal: JNCI Journal of the National Cancer Institute (1978)

The nitrosourea derivatives 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037), 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Me-CCNU; NSC-95441), and 1-methyl-1-nitrosourea (MNU; NSC-23909) were screened for mutagenic potential with Salmonella typhimurium strains G46 and TA1530 in vitro and in vivo. All four agents were mutagenic in vitro; MNU, CCNU, and Me-CCNU were also mutagenic in the host-mediated assay. Four additional chemotherapeutic nitrosoureas were tested in vitro, three of which were mutagenic. The lack of activity of the fourth agent was probably a reflection of its stability in solution rather than a true indication of mutagenic potential. All eight agents were tested in a repair test with S. typhimurium strains TA1978 and TA1538. Results of this test were negative, reflecting the insensitivity of these strains to ethylating and methylating agents. The insensitivity of the host-mediated assay is also discussed.
Neuroendocrine Tumors
Authors: Orlo H Clark, Al B Benson, Jordan D Berlin, Michael A Choti, Gerard M Doherty, Paul F Engstrom, John F Gibbs, Martin J Heslin, Anne Kessinger, Matthew H Kulke, Larry Kvols, Riad Salem, Leonard Saltz, Manisha H Shah, Stephen Shibata, Jonathan R Strosberg, James C Yao
Journal: Journal of the National Comprehensive Cancer Network (2009)

Neuroendocrine tumors affect cells throughout the nervous and endocrine systems that produce and secrete regulatory hormones. Common sites of origin include the endocrine pancreas; parathyroid, adrenal, and pituitary glands; calcitonin-producing cells of the thyroid (causing medullary thyroid carcinoma); and argentaffin cells of the gut (causing carcinoid tumors). Neuroendocrine tumors are rare and can be broadly subdivided into those with and those without a clinical syndrome. Most neuroendocrine tumors are malignant and metastasize commonly to lymph nodes and the liver or less commonly to bone, lung, brain, and other organs. Despite the widespread metastasis, these tumors are typically slow-growing and often have an insidious presentation. These guidelines discuss the diagnosis and management of neuroendocrine tumors and special considerations relating to these tumors; important updates include expanded information on octreotide use and a new algorithm on neuroendocrine tumors of unknown primary.For the most recent version of the guidelines, please visit NCCN.org
Acute Myocardial Infarction During Operation
Authors: H M SNYDER, R C CAMISHION, W F BALLINGER
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OC-003 Short-term results of 2032 single port colorectal procedures with preoperative risk profiling: ecspect prospective multicentre registry
Authors: H Weiss, K Gash, A Dixon, T Hell, R Zorron, K-H Vestweber, B Vestweber, L Boni, W Brunner
Journal: Gut (2015)

<h3>Introduction</h3> Minimally invasive surgery aims to reduce tissue trauma, minimise incision related complications and result in better cosmesis. Single port colorectal surgery (SPCS) has developed in recent years and despite being theoretically comparable to laparoscopic techniques the published literature lacks robust evaluation of SPCS and current data is insufficient to support its indication as a valid therapeutic method. The international group ECSPECT (European Consensus of Single Port Expertise in Colorectal Treatment) was created to provide a prospective registry in experienced centres using the SPCS technique to evaluate its feasibility, safety, risk factors, and short term oncologic adequacy. <h3>Method</h3> A prospective registry documented 2032 consecutive cases of single port colorectal resections from 11 European centres, over a four year-period. Centres were selected based on experience, defined as having completed more than 100 cases of SPCS. Intraoperative and postoperative data were recorded prospectively. Statistical analysis of risk factors, technique variables and short term results was performed. A Risk Chart was created to analyse the occurrence of conversions and complications in 1769 SPCS and validated utilising another 263 SPCS procedures. <h3>Results</h3> SPCS was performed for 937 benign and 832 malignant indications. Conversions to open surgery occurred in 4.24%. Complications occurred in 12.9%. Of these, 47.3% were Clavien-Dindo classification Type I-II, and 52.7% were Type III-V. Death occurred in eight patients (0.45%), with 3 of these attributed to surgical causes. Multivariate analysis identified male gender, higher BMI, higher ASA scores and rectal procedures as independent risk factors for conversion and complications. Gender adjusted Risk Charts were established to enable preoperative individualised evaluation of potential risks and thus to the indications for SPCS. <h3>Conclusion</h3> This is the largest prospective multicentre study of single port colorectal surgery in the literature to date. We have identified risk factors for adequate selection criteria to safely perform single port surgery for both benign and malignant colorectal conditions. The treatment of colorectal diseases through single port techniques proved feasible and safe across all of the centres included in the study. Single Port Surgery is a promising new therapy that can be used in appropriate colorectal patients to improve patient care. <h3>Disclosure of interest</h3> None Declared.
CBM-02THE PROGNOSTIC VALUE OF PERIPHERAL BLOOD ACTIVATED CD38<sup>+</sup>HLA-DR<sup>+</sup>CD8<sup>+</sup>T CELLS IN PATIENTS WITH GLIOMAS
Authors: Yen-Ya Chen, Hung-Bo Hsiao, Hsiu-Chi Chen, Chiung-Yin Huang, Chun-Yen Lin, Kuo-Chen Wei, Pin-Yuan Chen
Journal: Neuro-Oncology (2015)

BACKGROUND: Cytotoxic CD8+ T cells play an important role in antitumor immunity. However, the impact of activated CD8+ T cells on the prognosis of glioma patients remains uncertain. We examined the activated CD38+ HLA-DR+ CD8+ T cells in preoperative peripheral blood and determined whether these cells could predict the prognosis of patients with glioma. METHODS: This prospective study included 72 patients with gliomas (grade II n = 14; grade III n = 15; grade IV n = 43; mean age at diagnosis, 52.3 ± 14.0 years) and 17 healthy participants from June 2013 to December 2014. The CD38+ HLA-DR+ CD8+ subsets were retrieved from peripheral blood of glioma patients before tumor resection and were analyzed by conducting flow cytometry using anti-CD8, anti-CD38, anti-HLA-DR, anti-CCR5, anti-TNFR2, anti-Tim3 and anti-Ki67 antibodies. We evaluated immune profiles and clinical characteristics of recruited patients. The Wald-Wolfowitz runs test, multivariable linear regression model, and survival analysis were performed for data analyses. RESULTS: The activated phenotype (CD38+/HLA-DR+) CD8+ T cells were increased in grade IV patients compared to healthy controls (p <0.05). The activated CD8+ T cells expressed elevated level of CCR5 in low grade and high grade gliomas (all p <0.05). The proportion of the activated CD8+ T cells was associated with tumor size, age, and clinical outcomes. In grade IV patients, higher level of activated CD8+ T cells yielded better progression free survival (p <0.05). CONCLUSIONS: The findings of this study support that the expression of activation markers CD38+/HLA-DR+ on CD8+ T cells may predicted the prognosis of patients with gliomas, especially in high grade gliomas. Additional investigations are warranted to understand the associations between crucial immune mediators and the activated CD8+ T cells in glioma immunology.
A Fluorescence-Guided Laser Ablation System for Removal of Residual Cancer in a Mouse Model of Soft Tissue Sarcoma
Authors: Alexander L. Lazarides, Melodi J. Whitley, David B. Strasfeld, Diana M. Cardona, Jorge M. Ferrer, Jenna L. Mueller, Henry L. Fu, Suzanne Bartholf DeWitt, Brian E. Brigman, Nimmi Ramanujam, David G. Kirsch, William C. Eward
Journal: Theranostics (2015)

The treatment of soft tissue sarcoma (STS) generally involves tumor excision with a wide margin. Although advances in fluorescence imaging make real-time detection of cancer possible, removal is limited by the precision of the human eye and hand. Here, we describe a novel pulsed Nd:YAG laser ablation system that, when used in conjunction with a previously described molecular imaging system, can identify and ablate cancer in vivo. Mice with primary STS were injected with the protease-activatable probe LUM015 to label tumors. Resected tissues from the mice were then imaged and treated with the laser using the paired fluorescence-imaging/ laser ablation device, generating ablation clefts with sub-millimeter precision and minimal underlying tissue damage. Laser ablation was guided by fluorescence to target tumor tissues, avoiding normal structures. The selective ablation of tumor implants in vivo improved recurrence-free survival after tumor resection in a cohort of 14 mice compared to 12 mice that received no ablative therapy. This prototype system has the potential to be modified so that it can be used during surgery to improve recurrence-free survival in patients with cancer.
Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity
Authors: Susann Szmania, Amy D Greenway, Joshuah D Lingo, Katie Stone, Junaid Khan, Tarun K. Garg, Nathan M Petty, Susan B. Panozzo, Emily Woods, Jessica Warden, Joshua Epstein, Bart Barlogie, Frits van Rhee
Journal: Blood (2013)
Psychiatric malpractice: a review of the national loss experience
Authors: P F Slawson, F G Guggenheim
Journal: American Journal of Psychiatry (1984)

The authors examine the outcome of 217 malpractice actions against psychiatrists from 1974 to 1978. Claims against psychiatrists represented only 0.3% of the 71,788 claims against all physicians. Loss experience was developed as a function of procedure (ECT, psychotherapy), type of injury (suicide, diagnostic error), and the patient's psychiatric diagnosis. Over one-third of the claims were closed without payment; the average paid indemnity was $31,000. Diagnostic errors and suicide were the major sources of loss. Only a few cases went to trial. These data illustrate that psychiatry has one of the best malpractice claim records.
Erythrocyte catechol O-methyltransferase activity in schizophrenia: analysis of family data
Authors: M Baron, R Gruen, M Levitt, C Hunter, L Asnis
Journal: American Journal of Psychiatry (1984)

The authors determined the erythrocyte catechol O-methyltransferase (COMT) activity of 38 chronic schizophrenic patients, 69 of their first-degree relatives, and 39 normal controls. COMT activity did not distinguish patients from controls. Within families, COMT activity was not associated with schizophrenia spectrum disorders. The data suggest that COMT activity is not an indicator of vulnerability to schizophrenia.
Placing Bets on Biotech
Authors: Karen Weintraub
Journal: Cancer Discovery (2011)

News iN depthenormous clinical trials of a heart disease or diabetes drug.By targeting one particular use with specific molecular targets, trials can be much smaller-and cheaper.Then, after FDA approval for one indication, firms may be able to expand a drug's use without hugely expensive trials, notes John Carroll, editor of the newsletter Fierce Biotech.He cites Novartis's success in expanding indications for its kidney cancer drug everolimus (Afinitor)-which received federal approval after phase III testing in just 410 patients-to breast and other cancers.Some clinical trials can begin by gathering a limited amount of data for a very small, orphan market, he says."Once you've got approval, you can keep on building.You don't see that in other areas much."Of course that approach doesn't always work, as Genentech is learning with its anti-angiogenesis drug bevacizumab (Avastin), initially okayed for use against metastatic colorectal cancer.Although the FDA subsequently approved Avastin for breast cancer as well, it is reconsidering that decision.Drug pricing also may be a challenge.Last year, stock analysts "swooned" when Dendreon released its metastatic prostate cancer drug sipleucel-T (Provenge) with a $93,000 price tag, Carroll of Fierce Biotech notes."People did the math on the $93,000 and came up with some blockbuster figures," he says.But partly because of sticker shock, sales have been much lower than expected, leading to layoffs and a meltdown in Dendreon stock.
Hypochondriacal patients' beliefs about good health
Authors: A J Barsky, R R Coeytaux, M K Sarnie, P D Cleary
Journal: American Journal of Psychiatry (1993)

The authors hypothesized that hypochondriacal patients mistakenly believe good health to be a symptom-free state and that they consider more symptoms to be indicative of disease than do nonhypochondriacal patients.The Health Norms Sorting Task was developed to assess the standard used to decide whether one is sick or healthy; the respondent must classify 24 common and ambiguous symptoms as "healthy" or "not healthy." This instrument demonstrated good test-retest reliability and intrascale consistency. It was then administered to 60 patients with DSM-III-R hypochondriasis and 60 nonhypochondriacal patients randomly selected from the same general medicine clinic.Hypochondriacal patients considered significantly more symptoms to be indicative of disease than did the comparison group. Health Norms Sorting Test scores were correlated with hypochondriacal symptoms, somatization, and self-reported bodily amplification (sensitivity to bodily sensation). Test scores were not related to aggregate medical morbidity, medical care utilization, or sociodemographic characteristics.These data are compatible with the hypothesis that patients with DSM-III-R hypochondriasis believe good health to be relatively symptom free and consider more symptoms indicative of sickness. This may contribute to some of the clinical features of hypochondriasis, including the numerous somatic symptoms, bodily preoccupation, resistance to reassurance, and pursuit of medical care.